Injecting Topical Exosomes and Growth Factors Risks Severe FDA Sanctions

An editorial published on February 5, 2026, in Dermatologic Surgery warns that injecting topical cosmetics, including stem-cell, human, or plant-derived exosomes and platelet-derived growth factors (PDGF), carries severe regulatory and medicolegal risks for aesthetic clinics. Currently, the Food and Drug Administration (FDA) has approved zero exosome products. While some providers use these topical formulations off-label during microneedle array treatments or via direct injection, the authors clarify that off-label guidelines do not apply to cosmetics because they lack an FDA-approved intended use. Any percutaneous injection that bypasses the cutaneous barrier and alters tissue structure automatically disqualifies a product from being registered as a cosmetic, legally redefining it as an unapproved drug or unauthorized device. This applies to nonsterile gels like Regranex (a recombinant human PDGF product) if injected. Undertaking these procedures exposes your practice to FDA sanctions, criminal penalties, malpractice liability, and disciplinary action by medical boards. To protect your license and business, restrict all topical exosome and growth factor products strictly to non-invasive, surface-level applications.

Source: Dermatologic Surgery, https://doi.org/10.1097/DSS.0000000000005008